Evaluation of febrile neutropenic attacks in a tertiary care medical center in Turkey.
暂无分享,去创建一个
[1] M. Akova. Emerging problem pathogens: A review of resistance patterns over time , 2006 .
[2] R. E. Warren,et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation , 1997, European Journal of Clinical Microbiology and Infectious Diseases.
[3] S. Harthug,et al. A multi-centre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility , 2005, Scandinavian journal of infectious diseases.
[4] N. Çetingül,et al. Meropenem Plus Amikacin Versus Piperacillin-Tazobactam Plus Netilmicin as Empiric Therapy for High-Risk Febrile Neutropenia in Children , 2004, Pediatric hematology and oncology.
[5] P. Pizzo,et al. Management of Infections in Immunocompromised Patients , 2000 .
[6] J. L. Fuentes-Allen,et al. Microbiological findings in febrile neutropenia. , 2000, Archives of medical research.
[7] H. Ariffin,et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. , 2000, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[8] E. Kansu,et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. , 1999, International journal of antimicrobial agents.
[9] B. Oppenheim. The changing pattern of infection in neutropenic patients. , 1998, The Journal of antimicrobial chemotherapy.
[10] M. Villasís-Keever,et al. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure. , 1998, Archives of medical research.
[11] M. Paesmans,et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies , 1997, British journal of haematology.
[12] L. Young,et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] G. Donowitz. Fever in the compromised host. , 1996, Infectious disease clinics of North America.
[14] A. Mohar,et al. Experience of an intravenous therapy team at the Instituto Nacional de Cancerología (Mexico) with a long-lasting, low-cost silastic venous catheter. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] P. Pizzo,et al. Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.
[16] J. Shenep,et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1991, The Journal of infectious diseases.
[17] L. Young,et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1990, The Journal of infectious diseases.
[18] S. Schimpff. Overview of empiric antibiotic therapy for the febrile neutropenic patient. , 1985, Reviews of infectious diseases.
[19] Jean-Guy Cyr,et al. Principles and Practice of Infectious Diseases , 1980 .
[20] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.